CLAIMS

1. Use of an anti-CD38 antibody for the manufacture of a medicament for treating a CD38-positive cancer in a human patient in need thereof in combination with an anti-TGF-β antibody or an antigen-binding fragment thereof, wherein

the anti-CD38 antibody or antigen-binding fragment thereof comprises a

heavy chain CDR1 (HCDR1), HCDR2, HCDR3, light chain CDR1 (LCDR1), LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively, and

the anti-TGF-β antibody or antigen-binding fragment thereof has HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively.

2. Use of an anti-TGF-β antibody or an antigen-binding fragment thereof for the manufacture of a medicament for treating a CD38-positive cancer in a human patient in need thereof in combination with an anti-CD38 antibody, wherein

the anti-CD38 antibody comprises heavy chain CDR1 (HCDR1), HCDR2, HCDR3, light chain CDR1 (LCDR1), LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively, and

the anti-TGF-β antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively.

3. The use of claim 1 or 2, wherein the anti-CD38 antibody comprises a heavy chain variable domain (V_H) and a light chain variable domain (V_L) comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; and wherein the anti-TGF-β antibody or

antigen-binding fragment thereof comprises a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

4. The use of claim 3, wherein the anti-CD38 antibody has a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and wherein the anti-TGF-β antibody has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively.

5. The use of any one of claims 1-4, wherein the anti-CD38 antibody comprises a human IgG_1 Fc region and the anti-TGF-β antibody comprises a human IgG_4 Fc region.

6. The use of any one of the preceding claims, wherein the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment are to be administered to the patient sequentially.

7. Use of an anti-CD38 antibody for the manufacture of a medicament for treating a CD38-positive cancer in a human patient in need thereof in combination with an anti-TGF-β antibody or an antigen-binding fragment thereof,

wherein the anti-CD38 antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and

wherein the anti-TGF-β antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively.

8. Use of an anti-TGF-β antibody or an antigen-binding fragment thereof for the manufacture of a medicament for treating a CD38-positive cancer in a human patient in need thereof in combination with an anti-CD38 antibody,

wherein the anti-CD38 antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and

wherein the anti-TGF-β antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively.

9. The use of any one of claims 1-8, wherein the a CD38-positive cancer is selected from the group consisting of multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, hairy cell leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, acute lymphocytic leukemia, melanoma, glioblastoma, lung cancer, cutaneous squamous cell carcinoma, colorectal cancer, breast cancer, ovarian cancer, head and neck cancer, hepatocellular carcinoma, urothelial cancer, and renal cell carcinoma.

10. The use of any one of claims 1-9, wherein the cancer is a hematological malignancy.

11. The use of claim 10, wherein the cancer is multiple myeloma.

12. The use of claim 11, wherein the treatment results in less bone destruction than treatment with the anti-CD38 antibody alone.

13. The use of claim 11, wherein the treatment results in bone healing.

14. The use of claim 11, wherein the treatment further comprises dexamethasone to be administered.

15. The use of any one of claims 1-14, wherein the cancer is refractory to treatment with Ab2 or daratumumab, or refractory to both treatment with Ab2 and treatment with daratumumab.

16. An article of manufacture comprising an anti-CD38 antibody and an anti-TGF-β antibody or an antigen-binding fragment thereof, wherein said article of manufacture is suitable for

treating a CD38-positive cancer in a patient in need thereof,

wherein the anti-CD38 antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 15-20, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 13 and 14, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 11 and 12, respectively; and

wherein the anti-TGF-β antibody

has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 5-10, respectively;

has a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively; or

has an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 1 and 2, respectively.